Login to Your Account

InDex Moves Kappaproct into Phase III Ulcerative Colitis Trial

By Cormac Sheridan
Staff Writer

Wednesday, March 7, 2012
InDex Pharmaceuticals AB is moving its lead drug candidate Kappaproct into a European Phase III trial in patients with chronic active ulcerative colitis who are unresponsive to other therapies.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription